Driving Point-of-care Decisions With RWE

ACT: Looking forward, how will real-world evidence (RWE) drive point-of-care decisions?

Gliklich: I love this question because one of the reasons we started OM1 was to both advance medical research, but also to personalize medicine. We think about point-of-care a lot. We developed this, what I would call a digital phenotyping platform called PhenOM and you can think of it as a single assay. Instead of many different AI models, it's one model, one model to rule them all. What it does is it looks for over 500 different dimensions of signals that almost look like a fingerprint, if you actually look at that, and then different areas of that fingerprint might be associated with diagnoses that either have been discovered or not, might be associated with likelihood to respond to a particular treatment or the risk of a particular event, one of things we predict now is the likelihood of death in two years or a cardiovascular event in the next two years. We can use it also to generate for any individual health trajectory, so I come in, I see the doctor for X, Y, and Z; we're doing this now in depression and we're doing it in joint surgery. As the physician is offering me a treatment or procedure, what's likely to happen to patients like me over the next ‘X’ period of time down to the key outcomes that I'm interested in. I think that this is going to personalize the treatment paradigm more so than anything we've seen to date, so that's really exciting.